Innovative Holdings Alliance, Inc. announced a Joint Venture Agreement with Synaptic OTC Sciences. Innovative and Synaptic have completed an Agreement that is mutually beneficial and in the best interest of its shareholders. Throughout 2015, Innovative researched many different opportunities and made significant inroads to implement growth initiatives and contingencies.

The company's initial focus will be on commissioning the development of nutraceutical products and therapies aimed at providing relief for a number of diverse ailments and maladies, including but not limited to chronic pain, sleep disorders, depression, Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorders (SAD). Through this new alliance, Innovative will be providing managerial, financial and marketing expertise for licensing a line of clinically tested, science- backed and branded medical cannabidiol (CBD) and hemp products. Incipient products will focus on chronic pain, defined as pain that persists longer than a month or two.

Recent studies, published by The Institute of Medicine and The Journal of Pain to name a few, show that the total costs related to chronic pain ranged from $560 to $635 billion dollars a year.